Current clinical evidence on interim fluorine-18 fluorodeoxy glucose positron emission tomography for advanced-stage Hodgkin lymphoma and diffuse large B-cell lymphoma to predict treatment outcomes

Teruhiko Terasawa, Hirokazu Nagai

Research output: Contribution to journalArticlepeer-review

6 Citations (Scopus)

Abstract

We assessed the quality of current evidence on fluorine-18 fluorodeoxy glucose positron emission tomography (FDG-PET) performed after a few cycles of chemotherapy for patients with advanced-stage Hodgkin lymphoma (HL) or diffuse large B-cell lymphoma (DLBCL) based on a recently published systematic review of the literature. There is a moderate level of evidence suggesting that interim PET has an excellent prognostic ability to predict treatment failures in low- to intermediate-risk advanced-stage HL patients. Evidence is insufficient for DLBCL due to the clinical heterogeneity of the primary studies. Interim PET should at present not be regarded as an established procedure and it still remains as an unproven test for routine clinical practice. Its use should currently be reserved for research studies where treatment strategies and imaging protocols are standardized.

Original languageEnglish
Pages (from-to)1750-1752
Number of pages3
JournalLeukemia and Lymphoma
Volume50
Issue number11
DOIs
Publication statusPublished - 01-11-2009
Externally publishedYes

All Science Journal Classification (ASJC) codes

  • Hematology
  • Oncology
  • Cancer Research

Fingerprint

Dive into the research topics of 'Current clinical evidence on interim fluorine-18 fluorodeoxy glucose positron emission tomography for advanced-stage Hodgkin lymphoma and diffuse large B-cell lymphoma to predict treatment outcomes'. Together they form a unique fingerprint.

Cite this